Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: Effects of probenecid pretreatment

British Journal of Clinical Pharmacology

Volumn 43, Issue 1, 1997, Pages 112-115

  Noormohamed, F H ^a   Youle, M S ^a   Higgs, C J ^a   Gazzard, B G ^a   Lant, A F ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

CMV; Foscarnet; HIV; Pharmacokinetics; Probenecid; Renal excretion

Indexed keywords

FOSCARNET; PROBENECID;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; STEADY STATE;

EID: 0031033530     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1997.tb00147.x     Document Type: Article

References (20)

1. Blanshard C: Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. J Acq Immun Defic Synd 1992; 5(suppl 1): S25-S28.
2. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. J Intern Med 1991; 115: 665-673.
3. Polis MA, De Smet MD, Baird BF, et al. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med 1993; 94: 175-180.
4. Bacigalupo A, Tedone E, Van Lint MT, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-788.
5. Gearhart MO, Sorg TB: Foscarnet-induced hypomagnesemia and other electrolyte disorders. Ann Pharmacol 1993; 27: 285-289.
6. Chrisp P, Clissold SP. Foscarnet. Drugs 1991; 41: 104-129.
7. Noormohamed FH, Piner C, Youle MS, Higgs C, Gazzard BG, Lant AF. Renal effects of intravenous foscarnet in HIV seropositive patients. Clin Sci 1995; 88: 15P.
8. Mizgala CL, Quamme GA. Renal handling of phosphate. Physiol Rev 1985; 65: 431-466.
9. Sjovall J, Bergdahl S, Movin G, Ogenstad S, Saarimaki M. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1989; 33: 1023-1031.
10. Noormohamed FH, Fuller GN, Lant AF. Effect of salt balance on renal and hemodynamic actions of benazepril in normal man. J Clin Pharmacol 1989; 29: 928-937.
11. Petterson KJ, Nordgren T, Westerlund D. Determination of phosphonoformate (foscarnet) in biological fluids by ion-paired, reversed-phase liquid chromatography. J Chromatogr 1989; 488: 447-455.
12. Noormohamed FH, Youle MS, Tang B, Martin-Munley S, Gazzard BG, Lant AF. Foscarnet induced changes in plasma concentrations ot total and ionized calcium and magnesium in HIV seropositive patients. Antiviral Therapy 1996; 1: 172-179.
13. Hellmann NS, Nsubuga PS, Baingana-Baingi DJ, et al. Single-dose ampicillin/sulbactam versus ceftriaxone as treatment for uncomplicated gonorrhoea in a Ugandan STD clinic population with a high prevalence of PPNG infection. J Trop Med Hyg 1995; 98: 95-100.
14. de Miranda P, Good SS, Yarchoan R, et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 1989; 46: 494-500.
15. Cundy KC, Petty BG, Fisher PE, et al Clinical pharmacokinetics of cidofovir in human immunodeficiency virus infected patients. Antimicrob Agents Chemother 1995; 39: 1247-1252.
16. Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother 1989; 33: 742-745.
17. Taburet A, Katlama C, Blanshard C, et al., Pharmacokinetics of foscarnet after twice daily administrations in the treatment of cytomegalovirus disease in acquired immunodeficiency syndrome patients. Antimicrob Agents Chemother 1992; 36: 1821-1824.
18. Sjovall J, Karlsson A, Ogenstad S, Sandstrom E, Saarimaki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 1988; 44: 65-73.
19. +-phosphate cotransport in opossum kidney cells. Am J Physiol 1992; 263: F301-F310.
20. Noormohamed FH, Youle MS, Tang B, Martin-Munley S, Gazzard BG, Lant AF. Foscarnet induced changes in plasma calcium and magnesium in HIV seropositive patients. Br J Clin Pharmacol 1995, 40: 502P.